COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB WITHOUT METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT

被引：0
|
作者：
Oksuz, E. [1 ]
Malhan, S. [1 ]
Yanik, L. [2 ]
Koc, E. [2 ]
Erdogan-Ciftci, E. [2 ]
Celik, H. [2 ]
Orfanos, P. [3 ]
机构：
[1] Baskent Univ, Ankara, Turkey
[2] Roche Mustahzarlari San AS, Istanbul, Turkey
[3] F Hoffmann La Roche, Basel, Switzerland
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1770
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS56
引用
收藏
页码：S297 / S297
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS TOCILIZUMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS TREATMENT
    Oksuz, E.
    Malhan, S.
    Yanik, L.
    Koc, E.
    Erdogan-Ciftci, E.
    Celik, H.
    Orfanos, P.
    [J]. VALUE IN HEALTH, 2018, 21 : S295 - S295
  • [2] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Diamantopoulos, Alex
    Finckh, A.
    Huizinga, T.
    Sungher, D. K.
    Sawyer, L.
    Neto, D.
    Dejonckheere, F.
    [J]. PHARMACOECONOMICS, 2014, 32 (08) : 775 - 787
  • [3] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Alex Diamantopoulos
    A. Finckh
    T. Huizinga
    D. K. Sungher
    L. Sawyer
    D. Neto
    F. Dejonckheere
    [J]. PharmacoEconomics, 2014, 32 : 775 - 787
  • [4] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS, IN COLOMBIA
    Gamboa, O.
    Barbosa, D.
    Parada, L.
    Latorre, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A563 - A563
  • [5] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB SUBCUTANEOUS AS FIRST LINE BIOLOGIC MONOTHERAPY FOR RHEUMATOID ARTHRITIS MANAGEMENT IN GREECE
    Athanasakis, K.
    Tarantilis, F.
    Skroumpelos, A.
    Kyriopoulos, J.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A671 - A671
  • [6] Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis
    Kawatkar, Aniket
    Yi, David
    Estrada, Erika
    Portugal, Cecilia
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 283 - 284
  • [7] A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
    Choi, HK
    Seeger, JD
    Kuntz, KM
    [J]. ARTHRITIS AND RHEUMATISM, 2000, 43 (10): : 2316 - 2327
  • [8] COST-EFFECTIVENESS ANALYSIS OF TOCILIZUMAB VERSUS INFLIXIMAB FOR THE PATIENTS WITH RHEUMATOID ARTHRITIS IN KAZAKHSTAN
    Bektur, C.
    Kayir, F.
    Nurgozhin, T.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A379 - A379
  • [9] Improved tolerance and cost-effectiveness of subcutaneous vs oral methotrexate in rheumatoid arthritis (RA) and juvenile rheumatoid arthritis (JRA).
    Robbins, OB
    Ferriss, JA
    Newman, E
    MaClary, S
    Ayoub, W
    Harrington, T
    Perruquet, J
    [J]. ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S75 - S75
  • [10] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
12345